Argenx stock reports USD 1.72 billion third-quarter sales pre-market
Published on 10/22/2026 at 08:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQuarterly results and conference call
- argenx reported USD 1.72 billion in third-quarter product net sales on October 22, 2026.
- Management scheduled a results conference call for 2:30 p.m. CET on October 22, 2026.
- Argenx stock trades pre-market at EUR 785.20 at 8:05 a.m. CEST at Lang & Schwarz on October 22, 2026.
On October 22, 2026, argenx SE reported third-quarter product net sales of USD 1.72 billion, up 54 percent year over year, in a GlobeNewswire press release. Argenx stock trades pre-market at EUR 785.20 at 8:05 a.m. CEST at Lang & Schwarz on October 22, 2026.
Third-quarter results
The company reported total operating income of USD 1.75 billion for the three months ended September 30, 2026, including USD 1.72 billion in product net sales. Operating profit was USD 486 million and profit for the period was USD 506 million. Argenx said combined research and development and selling, general and administrative expenses are now expected to be approximately USD 4 billion for 2026, including costs related to the Forte Biosciences acquisition. The figures and outlook were published in the release.
Ahead of the Xetra open
The pre-market indication is being monitored ahead of the German session. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Argenx stock.
How Argenx makes its money
Argenx develops immunology medicines and earns revenue from approved therapies such as VYVGART and VYVGART Hytrulo. Management will discuss the third-quarter results during a conference call at 2:30 p.m. CET on October 22, 2026, according to the company release. Market context: Market report AEX.
